| Literature DB >> 34591203 |
Kinnosuke Matsumoto1, Takayuki Shiroyama2, Noriyasu Hashida3, Kotaro Miyake1, Yuji Yamamoto1, Tomoki Kuge1, Midori Yoneda1, Makoto Yamamoto1, Yujiro Naito1, Yasuhiko Suga1, Kiyoharu Fukushima1, Shohei Koyama1, Kota Iwahori1, Haruhiko Hirata1, Izumi Nagatomo1, Yoshito Takeda1, Atsushi Kumanogoh1.
Abstract
We report a unique case of advanced non-small cell lung cancer that exhibited the opposite response to its unilateral choroidal metastases upon ramucirumab plus docetaxel treatment. A combination of cisplatin, pemetrexed, and pembrolizumab was administered as first-line treatment, resulting in shrinkage of all the lesions. However, although the patient was continued on a course of pembrolizumab, all the lesions had recurred approximately two months later. Ramucirumab plus docetaxel, administered as sequential treatment, resulted in maintained shrinkage of the choroidal lesions, yet all the other lesions progressed. Ramucirumab may be a suitable therapy for choroidal metastases, especially if administered immediately after immunotherapy.Entities:
Keywords: Case report; Choroidal metastasis; Docetaxel; Lung adenocarcinoma; Ramucirumab
Mesh:
Substances:
Year: 2021 PMID: 34591203 DOI: 10.1007/s10456-021-09820-7
Source DB: PubMed Journal: Angiogenesis ISSN: 0969-6970 Impact factor: 9.596